AbbVie reported full-year 2025 net revenues of $61.16 billion, an 8.6% increase from 2024, with combined Skyrizi and Rinvoq sales hitting $25.87 billion — already exceeding the company’s 2027 long-term guidance two years early. This article presents verified financial data from AbbVie SEC filings and earnings disclosures covering revenue, products, geography, and pipeline activity.
Key AbbVie Statistics 2026
- AbbVie posted $61.16 billion in full-year 2025 revenue, up 8.6% from $56.33 billion in 2024.
- Skyrizi global revenue reached $17.56 billion in 2025, growing 49.8% year over year.
- Rinvoq global revenue hit $8.30 billion in 2025, a 39.1% increase from 2024.
- Humira global revenue fell to $4.54 billion in 2025, down 49.5% from $8.99 billion in 2024.
- The immunology portfolio generated $30.41 billion in 2025, a 14.0% reported increase.
AbbVie Annual Revenue Trend (2022–2025)
AbbVie’s revenue collapsed in 2023 after Humira lost US patent exclusivity, then recovered in 2024 and accelerated in 2025. The 2025 figure of $61.16 billion is the highest in company history, surpassing the 2022 Humira-peak year by $3.1 billion.
The recovery came almost entirely from two replacement immunology drugs rather than from Humira stabilizing. Humira global revenue continued falling through 2025, declining another 49.5% on top of the 2023 drop.
| Year | Total Revenue | YoY Change | Key Driver |
|---|---|---|---|
| 2022 | $58.05 billion | — | Humira peak; full Allergan contribution |
| 2023 | $54.32 billion | -4.0% | US Humira biosimilar entry |
| 2024 | $56.33 billion | +7.0% | Skyrizi and Rinvoq growth |
| 2025 | $61.16 billion | +8.6% | Immunology and neuroscience scale-up |
Source: AbbVie Q4 2025 Earnings Release, February 4, 2026
How Much Revenue Did Skyrizi and Rinvoq Generate in 2025?
Skyrizi and Rinvoq combined for $25.87 billion in global sales in 2025, with Skyrizi alone clearing $17.56 billion. The pair already cleared the $25 billion 2027 target set by AbbVie management, and their growth pace shows little sign of slowing.
For context, Humira’s all-time peak was $21.24 billion in 2022. Skyrizi crossed the level Humira took two decades to reach in roughly six years on market.
| Drug | 2024 Revenue | 2025 Revenue | YoY Growth | Therapy Area |
|---|---|---|---|---|
| Skyrizi | $11.72 billion | $17.56 billion | +49.8% | Immunology |
| Rinvoq | $5.97 billion | $8.30 billion | +39.1% | Immunology |
| Humira | $8.99 billion | $4.54 billion | -49.5% | Immunology |
| Immunology total | $26.68 billion | $30.41 billion | +14.0% | — |
Source: AbbVie Q4 2025 Earnings Release, February 4, 2026
AbbVie Statistics by Product Portfolio
The neuroscience portfolio reached $10.77 billion in 2025, up 19.6%, driven by Vraylar, Botox Therapeutic, and the Ubrelvy-Qulipta migraine pair. Oncology was roughly flat at $6.66 billion as Imbruvica continued to decline.
Aesthetics — which includes Botox Cosmetic and Juvederm — was the only major segment to shrink, falling 6.1% to $4.86 billion as discretionary procedure spending stayed soft.
| Portfolio | 2024 Revenue | 2025 Revenue | YoY Change |
|---|---|---|---|
| Immunology | $26.68B | $30.41B | +14.0% |
| Neuroscience | $8.999B | $10.77B | +19.6% |
| Oncology | $6.555B | $6.655B | +1.5% |
| Aesthetics | $5.176B | $4.860B | -6.1% |
Source: AbbVie Q4 2025 Earnings Release, February 4, 2026
Top Selling AbbVie Products in 2025
Eight AbbVie products cleared $1 billion in global sales for 2025. Vraylar grew to $3.62 billion, Botox Therapeutic reached $3.77 billion, and the Ubrelvy-Qulipta migraine pair pulled in $2.31 billion combined. Pharmaceutical industry forecasts suggest immunology and migraine therapies will keep leading branded growth through 2027.
| Product | 2025 Global Revenue | Therapy Area |
|---|---|---|
| Skyrizi | $17.56 billion | Immunology |
| Rinvoq | $8.30 billion | Immunology |
| Humira | $4.54 billion | Immunology |
| Botox Therapeutic | $3.77 billion | Neuroscience |
| Vraylar | $3.62 billion | Neuroscience |
| Imbruvica | $2.87 billion | Oncology |
| Venclexta | $2.79 billion | Oncology |
| Botox Cosmetic | $2.72 billion | Aesthetics |
| Ubrelvy + Qulipta | $2.31 billion | Neuroscience |
Source: AbbVie Q4 2025 Earnings Release, February 4, 2026
AbbVie Statistics by Country
The United States made up 76.4% of AbbVie’s revenue in 2024, the most recent year for which the geographic breakdown is fully reported. Global healthcare spending data shows this US concentration is typical for branded biologics manufacturers.
Among named countries in 2024, the United Kingdom posted the strongest growth at 25.2%, followed by Germany at 15.7% and Japan at 11.3%. China was the only top-10 market to contract, falling 3.5% under volume-based procurement pressure.
| Country | 2023 Revenue | 2024 Revenue | YoY Change |
|---|---|---|---|
| United States | $41,883M | $43,029M | +2.7% |
| Germany | $1,266M | $1,465M | +15.7% |
| Japan | $1,008M | $1,122M | +11.3% |
| Canada | $1,076M | $1,088M | +1.1% |
| China | $950M | $917M | -3.5% |
| France | $780M | $776M | -0.5% |
| Spain | $501M | $528M | +5.4% |
| United Kingdom | $417M | $522M | +25.2% |
| Italy | $484M | $511M | +5.6% |
| Brazil | $439M | $464M | +5.7% |
| Australia | $472M | $463M | -1.9% |
Source: AbbVie 2024 Annual Report (Form 10-K)
AbbVie Quarterly Performance Through 2025
Revenue grew every quarter of 2025, peaking at $16.62 billion in Q4. Q4 alone beat the analyst consensus of $16.42 billion and contributed 27% of full-year sales.
The quarterly pattern shows immunology accelerating each period — Skyrizi alone went from $3.43 billion in Q1 to $5.01 billion in Q4. Biotech pipeline projections indicate this kind of late-year acceleration is unusual for a drug class that typically sees front-loaded reimbursement cycles.
| Quarter | Total Revenue | Skyrizi | Rinvoq | Humira |
|---|---|---|---|---|
| Q1 2025 | $13.34B | $3.43B | $1.72B | $1.12B |
| Q2 2025 | $15.00B | $4.42B | $2.03B | $1.18B |
| Q3 2025 | $16.20B | $4.71B | $2.18B | $0.99B |
| Q4 2025 | $16.62B | $5.01B | $2.37B | $1.25B |
Source: AbbVie Quarterly SEC Filings (Form 8-K), 2025
AbbVie R&D and Pipeline Statistics
AbbVie has invested more than $50 billion in R&D since the 2013 spinoff from Abbott Laboratories. The company employs 14,000+ scientists across 17 countries and runs research operations in over 170 markets globally.
The 2024 R&D ratio jumped meaningfully after a $4.5 billion impairment charge on emraclidine, a schizophrenia candidate that failed Phase II. That single write-down was 7.1× larger than the $630 million impairment AbbVie booked in 2023. Clinical trial attrition data shows central nervous system programs carry the highest Phase II failure rates among major therapy areas.
| Metric | Figure |
|---|---|
| Cumulative R&D investment since 2013 | $50 billion+ |
| Scientists and R&D professionals | 14,000+ |
| Research network countries | 17 |
| Emraclidine impairment (2024) | $4.5 billion |
| Comparison impairment (2023) | $630 million |
| US capital investment plan (2025) | $10 billion |
| New US manufacturing plant (Aug 2025) | $195 million |
| Biologics facility expansion (Sep 2025) | $70 million |
Source: AbbVie Press Releases and SEC Filings, 2024–2025
AbbVie Acquisitions and Strategic Activity
AbbVie completed two major pipeline acquisitions in 2024 — ImmunoGen for antibody-drug conjugate oncology and Cerevel Therapeutics for neuroscience — followed by Capstan Therapeutics in August 2025 and Gilgamesh Pharmaceuticals in October 2025.
The Capstan deal targeted an in vivo CD19 CAR-T platform, while Gilgamesh added next-generation mental health compounds. Pharma M&A activity trackers place AbbVie’s 2025 acquisition cadence among the most active in big pharma. The Allergan deal closed in May 2020 at $63 billion remains the largest in company history.
AbbVie Company Snapshot
| Metric | Figure |
|---|---|
| Founded | January 1, 2013 (spun from Abbott Laboratories) |
| NYSE ticker | ABBV |
| Total employees globally | 55,000 (Jan 2025) |
| Countries of operation | 170+ |
| Total revenue (2025) | $61.16 billion |
| Q4 2025 adjusted EPS | $2.71 |
| Full-year 2025 adjusted EPS | $10.00 |
| Largest acquisition | Allergan, $63 billion (May 2020) |
Source: AbbVie Q4 2025 Earnings Release and Company Disclosures
Pharmaceutical revenue rankings place AbbVie consistently among the top five global drugmakers by sales. The 2025 result widens the gap between AbbVie and the patent-cliff scenario most analysts forecast in 2022, when Humira biosimilars first entered the US market. Replacement revenue from Skyrizi and Rinvoq has more than offset the $16.7 billion Humira loss between 2022 and 2025.
Looking ahead, AbbVie has guided for 2026 adjusted EPS above Wall Street estimates, with continued double-digit growth expected from immunology and neuroscience. Biologics market forecasts through 2030 favor selective IL-23 inhibitors like Skyrizi over older anti-TNF biologics, supporting the company’s product mix.
FAQs
What is AbbVie’s revenue for 2025?
AbbVie reported full-year 2025 net revenues of $61.16 billion, an 8.6% increase from $56.33 billion in 2024. Q4 2025 revenue was $16.62 billion, beating the analyst consensus of $16.42 billion.
How much did Skyrizi and Rinvoq earn in 2025?
Skyrizi generated $17.56 billion globally in 2025, up 49.8%. Rinvoq generated $8.30 billion, up 39.1%. Combined sales of $25.87 billion already exceeded AbbVie’s 2027 long-term guidance by $0.5 billion.
How many people does AbbVie employ?
AbbVie employs approximately 55,000 people globally as of January 2025, including 14,000+ scientists and R&D professionals. The company operates in over 170 countries with research activity in 17.
How much has Humira revenue declined?
Humira global revenue fell to $4.54 billion in 2025 from $8.99 billion in 2024, a 49.5% decline. From its 2022 peak of $21.24 billion, Humira has lost roughly 79% of its global revenue in three years.
What was AbbVie’s largest acquisition?
The Allergan acquisition, completed in May 2020 for $63 billion, remains AbbVie’s largest. Recent deals include Cerevel Therapeutics and ImmunoGen in 2024, plus Capstan Therapeutics and Gilgamesh Pharmaceuticals in 2025.
Sources
AbbVie Q4 2025 Full-Year Earnings Release
AbbVie Investor Relations 2025 Annual Results
With many years of professional experience within transnational corporations in different industries, Richard Jaimes has had the opportunity to lead people and organizations, investigate future topics, create strategies and innovations, consult senior management and translate insights into business advantages. Richard is also a long time senior consultant with Quantumrun Foresight.
